Showing 3571-3580 of 7247 results for "".
- Bimekizumab Shows Durable Psoriasis Clearance and 3-Year HS Controlhttps://practicaldermatology.com/news/bimekizumab-shows-durable-psoriasis-clearance-and-3-year-hs-control/2486394/New analyses from the BE RADIANT and BE VIVID trials showed the durability of response with bimekizumab (Bimzelx; UCB) in treating plaque psoriasis, alongside positive long-term findings in hidradenitis suppurativa (HS). Resu
- ILDS, WHO Launch Global Dermatology Training Hub to Address Care Gapshttps://practicaldermatology.com/news/ilds-who-launch-global-dermatology-training-hub-to-address-care-gaps/2486380/The International League of Dermatological Societies (ILDS), in collaboration with the World Health Organization (WHO), has launched the ILDS Dermatology Training Hub, a free online platform aimed at expanding access to dermatology education worldwide. The initiati
- Study: Potential Link Between Lesional IgG Autoantibodies and HS Disease Severityhttps://practicaldermatology.com/news/study-suggests-potential-link-between-lesional-igg-autoantibodies-and-hs-disease-severity/2486348/A small biopsy-based study in the Journal of Investigative Dermatology Innovations adds to emerging evidence that humoral immunity may contribute to hidradenitis suppurativa (HS) pathobiology. Investigators analyzed
- Lutikizumab Improves Clinical Response Rates in Moderate to Severe HS: Analysishttps://practicaldermatology.com/news/lutikizumab-shows-promise-in-hs-after-anti-tnf-failure-in-phase-2-trial/2486330/In a phase 2, double-blind, placebo-controlled randomized clinical trial, lutikizumab demonstrated efficacy signals in adults with moderate to severe hidradenitis suppurativa (HS) who had previously experienced anti–tumor necrosis factor (TNF) therapy failure.
- FDA Expands Secukinumab to Adolescents With Moderate to Severe HShttps://practicaldermatology.com/news/fda-expands-secukinumab-to-adolescents-with-moderate-to-severe-hs/2486084/The US Food and Drug Administrationv (FDA) has approved secukinumab (Cosentyx, Novartis) for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa (HS), becoming the only IL-17A inhibitor approved for this group, according to a
- Review: Gut Microbiota Dysbiosis Linked With AD, Psoriasis, and HShttps://practicaldermatology.com/news/review-gut-microbiota-linked-with-dysbiosis-with-ad-psoriasis-and-hs/2485997/A new systematic review suggests that alterations in gut microbial composition may contribute to atopic dermatitis (AD), psoriasis, and hidradeni
- Diclofenac, Silymarin Show Promise for Preventing Chemotherapy-Induced Hand-Foot Syndrome: Meta-analysishttps://practicaldermatology.com/news/diclofenac-silymarin-show-promise-for-preventing-chemotherapy-induced-hand-foot-syndrome-meta-analysis/2485939/Diclofenac and topical silymarin reduced the risk of grade 2 or higher chemotherapy-induced hand-foot syndrome (HFS), according to a new meta-analysis of randomized clinical trials evaluating pharmacologic preventive strategies.
- Study: Tumor Location and Histologic Features Linked to Melanoma Recurrencehttps://practicaldermatology.com/news/study-tumor-location-and-histologic-features-linked-to-melanoma-recurrence/2485922/In patients with stage I–II melanoma, tumor location and histopathologic features were linked with recurrence risk beyond traditional factors such as ulceration and tumor thickness, according to a new study. Investigators exa
- Arcutis Launches First-in-Human Trial of CD200R Agonist ARQ-234 in Atopic Dermatitishttps://practicaldermatology.com/news/arcutis-launches-first-in-human-trial-of-cd200r-agonist-arq-234-in-atopic-dermatitis/2485894/Arcutis Biotherapeutics announced today that it has enrolled the first participant in a phase 1a/1b clinical trial evaluating ARQ-234, an investigational CD200 receptor (CD200R) agonist, in healthy volunteers and adults with moderate to severe atopic dermatitis (AD
- Study: Bimekizumab Not Linked to Higher Depression Risk vs. IL-23 Inhibitorshttps://practicaldermatology.com/news/study-bimekizumab-not-linked-to-higher-depression-risk-vs-il-23-inhibitors/2485849/Bimekizumab was not associated with increased risk of depression or suicidal ideation compared with IL-23 inhibitors, a new study from George Washington University indicated. "Bimekizumab, a dual IL-17A/F inhibitor, has demons